RaDiCo-PID - Idiopathic Interstitial Pneumonia: From Infancy to Elderly

Head :
CLEMENT Annick, Inserm UMR S 933

Last update : 01/03/2017 | Version : 1 | ID : 73380


Export to XML

Please choose the format :

CSV (Excel)

Export to CSV

What sections do you want to export ?

General Aspects
Scientific investigator(s) (Contact)
Governance of the database
Additional contact
Type of database
Database objective
Population type
Size of the database
Select all | Invert selection | No selection

Which version do you want to export ?

French version
Detailed name Idiopathic Interstitial Pneumonia: From Infancy to Elderly
Sign or acronym RaDiCo-PID
CNIL registration number, number and date of CPP agreement, AFSSAPS (French Health Products Safety Agency) authorisation CCTIRS n° 16.050Bis
General Aspects
Medical area Otolaryngology or ENT
Rare diseases
Pathology (details) Idiopathic Interstitial Pneumonia: Idiopathic Interstitial Pneumonia (IIP), known in French as “Pneumopathies Interstitielles Diffuses (PID)” and referred in the current protocol as IPP/PID, encompass a group of diffuse infiltrative lung diseases of unknown origin that affect the lung architecture and are characterized by a progressive and often irreversible remodeling of the lung. Clinical expression includes mainly dyspnea, restriction on pulmonary function testing, impaired haematosis and radiologic diffuse lung infiltration. In most situations, these diffuse lung disorders are chronic, with high morbidity and mortality due to the lack of curative therapy.
Health determinants Climate
Healthcare system and access to health care services
Lifestyle and behavior
Social and psychosocial factors
Scientific investigator(s) (Contact)
Name of the director CLEMENT
Surname Annick
Address Hôpital Armand Trousseau
Service de pneumologie pédiatrique
26 Avenue du Dr Arnold Netter
75012 Paris
Phone +33 (0)1 44 73 66 68
Email annick.clement@aphp.fr
Unit Inserm UMR S 933
Organization Institut National de la Santé et de la Recherche Médicale / French National Institute for Health and Medical Research (Inserm)
Participation in projects, networks and consortia Yes
Details Filière de Santé Maladies Rares pulmonaires RespiFil / European Reference Network ERN-LUNG
Funding status Public
Details Funded by the French « Investissements d’Avenir » cohorts programme, Grant « ANR » 10-COHO-0003.
Governance of the database
Sponsor(s) or organisation(s) responsible Institut National de la Santé et de la Recherche Médicale / French National Institute for Health and Medical Research (Inserm)
Organisation status Public
Presence of scientific or steering committees Yes
Labelling and database evaluation Security audit certification of the database
Additional contact
Main features
Type of database
Type of database Morbidity registers
Additional information regarding sample selection. The goal of the IIP/PID cohort is to include prevalent and incident IIP/PID cases diagnosed in paediatric patients and adult patients. For the prevalent cases and the retrospective nature of the data, a diagnosis validation will be required.
Paediatric patient population
Pediatric IIP/PID patients include all patients with diffuse parenchymal diseases linked to rare conditions others than immune deficiencies, proliferative disorders, metabolic disorders, and drug toxicity.
Since the first description of the RespiRare IIP/PID paediatric cases, almost 400 patients (prevalent cases) have been included in the database. Around 60-80 new IIP/PID cases (incident cases) are currently reported per year. However, this number is underestimated, and will most likely increase with the identification of more adapted diagnostic criteria.
Adult patient population
For IIP/PID patients with IPF (approximately two thirds of the IIP/PID adult patients): considering the relatively large number of patients mainly aged and with a very poor prognosis, only prospective data will be collected to maximize the longitudinal collection of data and allow a detailed and accurate description of disease evolution in this population.
For IIP/PID patients without IPF but with diffuse parenchymal diseases linked to rare conditions others than immune deficiencies, proliferative disorders, metabolic disorders, and drug toxicity (approximately one third of the IIP/PID adult patients): IIP/PID, incident cases and prevalent cases (with retrospective data) will be included in the cohort.
About 2000 adult IIP/PID patients are expected to be recruited during this study.
Database objective
Main objective Primary Objective
The main objective is to describe the phenotypic features of the paediatric and adult patients with IIP/PID, at diagnosis and during the follow-up. These data will be critical for the description of the natural history of the various forms of IIP/PID.

Secondary Objectives
The secondary objectives are to:
• Identify gene factors involved in disease initiation and progression,
• Investigate the extent to which environmental and co-morbidity factors may influence disease severity and outcome
• Identify and validate biomarkers for disease diagnosis and progression

Exploratory objectives
• Production of improved strategies for patient recruitment and enrolment into clinical trials
• Development of novel strategy for patient follow-up
• Development of novel diagnostic approaches
• Evaluation of effect on natural history of disease, and tolerance of therapy, in a large population in real life
• Development of novel therapeutic approaches

Information Technology Objectives
• Develop and diffuse an electronic tool of data collection from various sources linked to a database integrating a system of management and follow-up of data-management allowing collection of data for IIP/PID paediatric and adult patients.
• Include data generated by patients and, where relevant, their parents and/or carers.
Inclusion criteria  Patient with a diagnosis of IIP/PID
IIP/PID diagnosis is established on presenting history, clinical, radiological and functional and if available pathological findings. Inclusion criteria include:
 Clinical criteria: chronic respiratory insufficiency manifestations including dyspnea/tachypnea, cough, and cyanosis during exercise or at rest
 Radiological criteria: characteristic chest High-Resolution Computed Tomography (HRCT) abnormalities including widespread ground glass or alveolar attenuation, reticulation often associated with traction bronchiectasis, and honeycombing
 Functional criteria: pulmonary function test abnormalities reflecting a restrictive pattern and including: loss of lung volume, vital capacity (VC), total lung capacity (TLC); reduction in the diffusion capacity of the lung for carbon monoxide (DLCO), gas exchange abnormalities, and altered ventilatory response to exercise
 Patients (parents/guardians for paediatric/patients) having given an informed consent to participate in the protocol
 Patients affiliated to the “Regime National d’Assurance Maladie”

Non-inclusion Criteria
 Patients with diffuse parenchymal lung diseases caused by drug toxicity, immunodeficiency, proliferative disorders including histiocytosis, and metabolic disorders
 Patients (parents/guardians for paediatric patient) not able to approve/understand the protocol

Population type
Age Newborns (birth to 28 days)
Infant (28 days to 2 years)
Early childhood (2 to 5 years)
Childhood (6 to 13 years)
Adolescence (13 to 18 years)
Adulthood (19 to 24 years)
Adulthood (25 to 44 years)
Adulthood (45 to 64 years)
Elderly (65 to 79 years)
Great age (80 years and more)
Population covered Sick population
Pathology J84 - Other interstitial pulmonary diseases
Gender Male
Geography area National
Detail of the geography area Complete national coverage through the network of rare pulmonary disease reference and ciompetence centers
Data collection
Date of first collection (YYYY or MM/YYYY) 2017
Date of last collection (YYYY or MM/YYYY) 2021 minimum
Size of the database
Size of the database (number of individuals) [1000-10 000[ individuals
Details of the number of individuals 2700
Database activity Current data collection
Type of data collected Clinical data
Declarative data
Paraclinical data
Biological data
Administrative data
Clinical data (detail) Direct physical measures
Medical registration
Details of collected clinical data This is a national multi-centric non interventional study, built on a model of observational longitudinal study, descriptive, retrospective and prospective allowing to collect homogenous clinical, biological, treatment, environmental, and quality of life data from paediatric and adult patients with idiopathic interstitial pneumonia associated to biological data collection: from blood (DNA samples, serum), biopsies and broncho-alveolar liquid (BAL) analyses.
Declarative data (detail) Paper self-questionnaire
Internet self-questionnaire
Face to face interview
Details of collected declarative data SF36 or SF10 + St George’s Hospital
Biological data (detail) Record of biological results (hematology, biochemical, immunity, serology); Record of results for: bacteriology, virology, parasitology, mycology, bronchoscopy, bronchoalveolar lavage examination; Record of lung function tests, arterial blood gas and spirometry (If available sleep gas exchange and polysomnography); If available/performed, records of results for lung tissue examination, lung biopsy (surgical, transbronchial), lung explant; If available/performed, records of other organ function evaluation (including digestive and cardiac examinations)
Presence of a biobank Yes
Contents of biobank Serum
Fluids (saliva, urine, amniotic fluid, …)
Details of biobank content plus broncho alveolar liquids
Health parameters studied Health event/morbidity
Health event/mortality
Quality of life/health perception
Data collection method eCRF using REDCap; Cloud based, secure by design, web accessible platform. Certified Health Data Hosting resource
Classifications used HPO, ICD10, Snomed CT, Orpha Codes and ORDO, Drug dictionary (DCIs)
Quality procedure(s) used Continuous data management; Data Management Plan and Data Validation Plan. Native controls and Query system
Participant monitoring Yes
Monitoring procedures Monitoring by convocation of the participant
Monitoring by contact with the referring doctor
Monitoring by crossing with a medical-administrative database
Links to administrative sources No
Promotion and access
Presence of document that lists variables and coding procedures Yes
Terms of data access (charter for data provision, format of data, availability delay) Access requests to RaDiCo-PID data (rough / structured), biocollections or to analytic reports will be examined by the scientific committee following submission of a Specific Research Project (SRP) synopsis, as defined in the Resource Access Charter. Must be sent to pid@radico.fr
Access to aggregated data Access on specific project only
Access to individual data Access on specific project only

Partners - FAQ - Contact - Site map - Legal notices - Administration - Updated on December 15 2020 - Version 4.10.05

View Edit Create here